We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Reducing Beta-secretase Reverses Alzheimer's Disease in Model

By LabMedica International staff writers
Posted on 01 Mar 2018
Print article
Image: The brain of a 10-month-old mouse with Alzheimer\'s disease (left) is full of amyloid plaques (red) surrounded by activated microglial cells (green). But these hallmarks of Alzheimer\'s disease are reversed in animals that have gradually lost the BACE1 enzyme (right) (Photo courtesy of The Cleveland Clinic and Rockefeller University Press).
Image: The brain of a 10-month-old mouse with Alzheimer\'s disease (left) is full of amyloid plaques (red) surrounded by activated microglial cells (green). But these hallmarks of Alzheimer\'s disease are reversed in animals that have gradually lost the BACE1 enzyme (right) (Photo courtesy of The Cleveland Clinic and Rockefeller University Press).
Employing a complex series of mouse models, a team of neurological disease researchers showed that reducing the level of the enzyme beta-secretase (BACE1) could reverse the clinical symptoms of Alzheimer's disease (AD).

An important factor in the disease process in AD is the accumulation of amyloid beta (Abeta) protein. To form Abeta, amyloid precursor protein (APP) must be cut by two enzymes, beta-secretase and gamma-secretase. Drugs to block the beta-secretase enzyme (BACE inhibitors) in theory would prevent the buildup of beta-amyloid and may help slow or stop Alzheimer's disease. However, results from studies on BACE inhibitors have raised the possibility that the drugs currently being investigated for the treatment of Alzheimer's may have significant side effects related to impaired motor coordination.

Since mice that completely lack BACE1 suffer severe neurodevelopmental defects, investigators at the Cleveland Clinic (OH, USA) examined the possibility that inhibiting BACE1 in adult animals might be less harmful. To this end, they generated a strain of mice that gradually lost this enzyme as they grew older.

The investigators crossed these mice with a strain that started to develop amyloid plaques and Alzheimer's disease when they were about 75 days old. They reported in the February 14, 2018, online edition of the Journal of Experimental Medicine that the resulting offspring also formed plaques at this age, even though their BACE1 levels were approximately 50% lower than normal. However, the plaques began to disappear as the mice aged and lost BACE1 activity, until, at 10 months of age, the mice had no plaques in their brains at all.

This reversal in amyloid deposition caused significant improvement in gliosis and neuritic dystrophy. Moreover, synaptic functions, as determined by long-term potentiation and contextual fear conditioning experiments, were significantly improved, correlating with the reversal of amyloid plaques.

"To our knowledge, this is the first observation of such a dramatic reversal of amyloid deposition in any study of Alzheimer's disease mouse models," said senior author Dr. Riqiang Yan, now professor of neuroscience at the University of Connecticut (Storrs, USA). "Our study provides genetic evidence that preformed amyloid deposition can be completely reversed after sequential and increased deletion of BACE1 in the adult. Our data show that BACE1 inhibitors have the potential to treat Alzheimer's disease patients without unwanted toxicity. Future studies should develop strategies to minimize the synaptic impairments arising from significant inhibition of BACE1 to achieve maximal and optimal benefits for Alzheimer's patients."

Related Links:
Cleveland Clinic
University of Connecticut

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.